New drug aims to fix calcium imbalance after neck surgery
NCT ID NCT05735015
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called encaleret in 13 adults with post-surgical hypoparathyroidism, a condition where damaged parathyroid glands cause low blood calcium. Participants took the drug for 5 days while staying in the clinic, with frequent blood and urine tests. The goal was to see if encaleret could help balance calcium levels without the kidney risks of standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- encaleret
- What this could lead to
- If successful, encaleret could offer a new way to manage calcium levels in people with post-surgical hypoparathyroidism, potentially reducing kidney problems from current treatments.
- What could go wrong
- This is a small, early-phase study with only 13 participants, so results may not apply to everyone. The drug's long-term safety and effectiveness are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-SURGICAL HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.